-Highly unlikely Selecta will ever launch a product. I can’t elaborate on why I believe this though
-Shift in focus over the years is a symptom of a biotech which has struggled to define itself after major failures
-90%+ stock price dip from IPO and fleeing institutional investors hamper ability to acquire funding
-Major issues uncovered which never should have been issues to begin with, some of which were egregious
-Location isn’t great for public transit users